Scandinavian Biopharma expands its product portfolio with an immunosuppressive drug

Scandinavian Biopharma recently entered into a distribution agreement with Neovii Pharmaceuticals AG, a fully integrated global biopharmaceutical organization based in Switzerland, and has expanded its product offering to include Neovii’s GRAFALON®.

“With GRAFALON® we offer an immunosuppressive drug with a proven track record that is well established in the hospital market. This product is unique since it is registered for use in both organ and stem-cell transplantation”, says Björn Sjöstrand, CEO at Scandinavian Biopharma. In solid organ transplantation, GRAFALON® can help prevent organ rejection or suppress active rejection. In stem cell transplantation, it is used to suppress the reaction of the transplanted cells against the patient´s own cell (graft-versus-host disease or GvHD).

GRAFALON® is a polyclonal antibody that contains a combination of different antibodies targeting multiple pathways of disease. It is therefore used to suppress immune reactions leading to organ rejection or GvHD.

“By adding GRAFALON® we strength our offering to transplantation centers in Sweden and we will accelerate our growth in the distribution business even further”, says Björn Sjöstrand.”

For more information, please contact:
Björn Sjöstrand, CEO: +46 727-125 120, bjorn.sjostrand@scandinavianbiopharma.se




Go to MyNewsdesk

We are a research-based specialty biopharma company determined to give people worldwide a longer and better life.